The effect of transient increases in kynurenic acid and quinolinic acid levels early in life on behavior in adulthood: Implications for schizophrenia

Schizophrenia Research

Volumn 150, Issue 2-3, 2013, Pages 392-397

  Iaccarino, Hannah F ^a,d   Suckow, Raymond F ^b   Xie, Shan ^c   Bucci, David J ^a  

^a Dartmouth College   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Attention; Glia; Learning; Memory; Schizophrenia; Social

Indexed keywords

KYNURENIC ACID; KYNURENINE; QUINOLINIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BLOOD LEVEL; CONDITIONING; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; FEAR CONDITIONING; FEMALE; LOCOMOTION; NONHUMAN; ORIENTING RESPONSE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SOCIAL ATTITUDE; SOCIAL INTERACTION;

ATTENTION; GLIA; LEARNING; MEMORY; SCHIZOPHRENIA; SOCIAL;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; ATTENTION; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; COHORT STUDIES; CONDITIONING (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; FEAR; FEMALE; INTERPERSONAL RELATIONS; KYNURENIC ACID; MOTOR ACTIVITY; PREGNANCY; QUINOLINIC ACID; RATS; RATS, LONG-EVANS;

EID: 84886245645     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.09.004     Document Type: Article

References (62)

1. Adams C.E. Comparison of alpha7 nicotinic acetylcholine receptor development in the hippocampal formation of C3H and DBA/2 mice. Brain Res. Dev. Brain Res. 2003, 143(2):137-149.
2. Akagbosu C.O., Evans G.C., Gulick D., Suckow R.F., Bucci D.J. Exposure to kynurenic acid during adolescence produces memory deficits in adulthood. Schizophr. Bull. 2012, 38:769-778.
3. Alexander K.S., Wu H.Q., Schwarcz R., Bruno J.P. Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. Psychopharmacology 2012, 220(3):627-637.
4. Alexander K.S., Pocivavsek A., Wu H.Q., Pershing M.L., Schwarcz R., Bruno J.P. Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantamine. Neuroscience 2013, 238:19-28.
5. Asp L., Beraki S., Kristensson K., Ogren S.O., Karlsson H. Neonatal infection with neurotropic influenza A virus affects working memory and expression of type III Nrg1 in adult mice. Brain Behav. Immun. 2009, 23(6):733-741.
6. Asp L., Holtze M., Powell S.B., Karlsson H., Erhardt S. Neonatal infection with neurotropic influenza A virus induces the kynurenine pathway in early life and disrupts sensorimotor gating in adult Tap1-/- mice. Int. J. Neuropsychopharmacol. 2010, 13(4):475-485.
7. Bast T., Zhang W.N., Feldon J. Dorsal hippocampus and classical fear conditioning to tone and context in rats: effects of local NMDA-receptor blockade and stimulation. Hippocampus 2003, 13:657-675.
8. Broide R.S., Leslie F.M. The alpha7 nicotinic acetylcholine receptor in neuronal plasticity. Mol. Neurobiol. 1999, 20(1):1-16.
9. Bucci D.J., Burwell R.D. Deficits in attentional orienting following damage to the postrhinal or perirhinal cortex. Behav. Neurosci. 2004, 118:1117-1122.
10. Chess A.C., Bucci D.J. Increased levels of cerebral kynurenic acid alter stimulus processing and conditioned responding in rats. Behav. Brain Res. 2006, 170:326-332.
11. Chess A.C., Simoni M.K., Alling T.E., Bucci D.J. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr. Bull. 2007, 33:797-804.
12. Chess A.C., Landers A.M., Bucci D.J. l-Kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning. Behav. Brain Res. 2009, 201:325-331.
13. Erhardt S., Blennow K., Nordin C., Skogh E., Lindstrom L.H., Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett. 2001, 313:96-98.
14. Erhardt S., Schwieler L., Emanuelsson C., Geyer M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol. Psychiatry 2004, 56:255-260.
15. Erhardt S., Olsson S.K., Engberg G. Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs 2009, 23(2):91-101.
16. Falls W.A., Carlson S., Turner J.G., Willott J.F. Fear-potentiated startle in two strains of inbred mice. Behav. Neurosci. 1997, 111(4):855-861.
17. File S.E. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J. Neurosci. Methods 1980, 2:219-238.
18. Gallagher M., Graham P.W., Holland P.C. The amygdala central nucleus and appetitive Pavlovian conditioning: lesions impair one class of conditioned behavior. J. Neurosci. 1990, 10(6):1906-1911.
19. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 2001, 156(2-3):117-154.
20. Heyes M.P., Markey S.P. Quantification of quinolinic acid in rat brain, whole blood, and plasma by gas chromatography and negative chemical ionization mass spectrometry: effects of systemic l-tryptophan administration on brain and blood quinolinic acid concentrations. Anal. Biochem. 1988, 174(1):349-359.
21. Hilmas C., Pereira E.F.R., Alkondon M., Rassoulpour A., Schwarcz R., Albuquerque E.X. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J. Neurosci. 2001, 21:7463-7473.
22. Holland P.C. Conditioned stimulus as a determinant of the form of the Pavlovian conditioned response. J. Exp. Psychol. Anim. Behav. Process. 1977, 3(1):77-104.
23. Holland P.C. Unblocking in Pavlovian appetitive conditioning. J. Exp. Psychol. Anim. Behav. Process. 1984, 10(4):476-497.
24. Holland P.C. Brain mechanisms for changes in processing of conditioned stimuli in pavlovian conditioning: implications for behavior theory. Anim. Learn. Behav. 1997, 25:373-399.
25. Holtze M., Asp L., Schwieler L., Engberg G., Karlsson H. Induction of the kynurenine pathway by neurotropic influenza A virus infection. J. Neurosci. Res. 2008, 86(16):3674-3683.
26. Hopkins M.E., Sharma M., Evans G.C., Bucci D.J. Voluntary physical exercise alters attentional orienting and social behavior in rat model of attention-deficit/hyperactivity disorder. Behav. Neurosci. 2009, 123:599-606.
27. Karlsson H. Viruses and schizophrenia, connection or coincidence?. Neuroreport 2003, 14(4):535-542.
28. Kaye H., Pearce J.M. The strength of the orienting response during Pavlovian conditioning. J. Exp. Psychol. Anim. Behav. Process. 1984, 10(1):90-109.
29. Keene C.S., Bucci D.J. Contributions of the retrosplenial and posterior parietal cortices to cue-specific and contextual fear conditioning. Behav. Neurosci. 2008, 122:89-97.
30. Komuro H., Rakic P. Modulation of neuronal migration by NMDA receptors. Science 1993, 260(5104):95-97.
31. Lang P.J., Simons R.G., Balaban M. Attention and Orienting: Sensory and Motivational Processes 1997, Erlbaum, Mahwah, NJ.
32. Lapin I.P., Mutovkina L.G., Ryzov I.V., Mirzaev S. Anxiogenic activity of quinolinic acid and kynurenine in the social interaction test in mice. J. Psychopharmacol. 1996, 10(3):246-249.
33. Levin E.D. Nicotinic receptor subtypes and cognitive function. J. Neurobiol. 2002, 53(4):633-640.
34. Linderholm K.R., Skogh E., Olsson S.K., Dahl M.L., Holtze M., Engberg G., Samuelsson M., Erhardt S. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr. Bull. 2012, 38(3):426-432.
35. Miller C.L., Llenos I.C., Dulay J.R., Barillo M.M., Yolken R.H., Weis S. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol. Dis. 2004, 15:618-629.
36. Miller C.L., Llenos I.C., Dulay J.R., Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 2006, 1073-1074:25-37.
37. Miller C.L., Llenos I.C., Cwik M., Walkup J., Weis S. Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. Neurochem. Int. 2008, 52:1297-1303.
38. Miller C.L., Murakami P., Ruczinski I., Ross R.G., Sinkus M., Sullivan B., Leonard S. Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder. Schizophr. Res. 2009, 113:259-267.
39. Müller N., Schwarz M.J. Immune system and schizophrenia. Curr. Immunol. Rev. 2010, 6(3):213-220.
40. Parsons C.G., Danysz W., Quack G., Hartmann S., Lorenz B., Wollenburg C., Baran L., Przegalinski E., Kostowski W., Krzascik P., Chizh B., Headley P.M. Novel systemically active antagonists of the glycine site of the N-methyl-d-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J. Pharmacol. Exp. Ther. 1997, 283(3):1264-1275.
41. Pereira E.F., Hilmas C., Santos M.D., Alkondon M., Maelicke A., Albuquerque E.X. Unconventional ligands and modulators of nicotinic receptors. J. Neurobiol. 2002, 53(4):479-500.
42. Pocivavsek A., Wu H.Q., Elmer G.I., Bruno J.P., Schwarcz R. Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood. Eur. J. Neurosci. 2012, 35(10):1605-1612.
43. Rassoulpour A., Wu H.Q., Ferre S., Schwarcz R. Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J. Neurochem. 2005, 93(3):762-765.
44. Rice D., Barone S.Jr Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ. Health Perspect. 2000, 108(Suppl. 3):511-533.
45. Sams-Dodd F. Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev. Neurosci. 1999, 10(1):59-90.
46. Sanchez J.T., Wang Y., Rubel E.W., Barria A. Development of glutamatergic synaptic transmission in binaural auditory neurons. J. Neurophysiol. 2010, 104(3):1774-1789.
47. Schwarcz R., Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J. Pharmacol. Exp. Ther. 2002, 303:1-10.
48. Schwarcz R., Rassoulpour A., Wu H.-Q., Medoff D., Tamminga C.A., Roberts R.C. Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry 2001, 50:521-530.
49. Schwarcz R., Guidetti P., Sathyasaikumar K.V., Muchowski P.J. Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington's disease. Prog. Neurobiol. 2010, 90(2):230-245.
50. Schwarcz R., Bruno J.P., Muchowski P.J., Wu H.Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 2012, 13(7):465-477.
51. Shepard P.D., Joy B., Clerkin L., Schwarcz R. Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 2003, 28:1454-1462.
52. Silver H., Feldman P., Bilker W., Gur R.C. Working memory deficit as a core neuropsychological dysfunction in schizophrenia. Am. J. Psychiatry 2003, 160:1809-1816.
53. Stone T.W. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 1993, 45:309-379.
54. Stone T.W., Perkins M.N. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur. J. Pharmacol. 1981, 72(4):411-412.
55. Thevandavakkam M.A., Schwarcz R., Muchowski P.J., Giorgini F. Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease. CNS Neurol. Disord. Drug Targets 2010, 9(6):791-800.
56. Trecartin K.V., Bucci D.J. Administration of kynurenine during adolescence, but not during adulthood, impairs social behavior in rats. Schizophr. Res. 2011, 133:156-158.
57. Vecsei L., Miller J., MacGarvey U., Beal F.M. Effects of kynurenine and probenecid on plasma and brain tissue concentrations of kynurenic acid. Neurodegeneration 1992, 1:17-26.
58. Waters F.A.V., Mayberry M.T., Badcock J.C., Michie P.T. Context memory and binding in schizophrenia. Schizophr. Res. 2004, 68:119-125.
59. Wonodi I., Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schizophr. Bull. 2010, 36(2):211-218.
60. Wu H.Q., Rassoulpour A., Schwarcz R. Effect of systemic l-DOPA administration on extracellular kynurenate levels in the rat striatum. J. Neural. Transm. 2002, 109(3):239-249.
61. Wu H.Q., Rassoulpour A., Schwarcz R. Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?. J. Neural. Transm. 2007, 114(1):33-41.
62. Yolken R.H., Torrey E.F. Are some cases of psychosis caused by microbial agents? A review of the evidence. Mol. Psychiatry 2008, 13(5):470-479.